Axsome Therapeutics, Inc. $AXSM Shares Purchased by Ensign Peak Advisors Inc

by · The Cerbat Gem

Ensign Peak Advisors Inc grew its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 104.4% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 30,595 shares of the company’s stock after purchasing an additional 15,630 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Axsome Therapeutics were worth $3,194,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Axsome Therapeutics in the 1st quarter worth about $25,000. Quantbot Technologies LP bought a new position in Axsome Therapeutics in the 1st quarter worth about $31,000. AlphaQuest LLC acquired a new stake in shares of Axsome Therapeutics in the first quarter valued at approximately $38,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Axsome Therapeutics during the first quarter valued at approximately $47,000. Finally, Ameritas Advisory Services LLC acquired a new position in shares of Axsome Therapeutics during the second quarter worth approximately $77,000. Institutional investors own 81.49% of the company’s stock.

Insider Activity at Axsome Therapeutics

In related news, CEO Herriot Tabuteau sold 21,775 shares of the firm’s stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $134.49, for a total transaction of $2,928,519.75. Following the completion of the sale, the chief executive officer directly owned 7,229 shares in the company, valued at approximately $972,228.21. This trade represents a 75.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Mark L. Jacobson sold 10,000 shares of the company’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $115.96, for a total value of $1,159,600.00. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 370,577 shares of company stock valued at $46,235,199. Company insiders own 22.30% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AXSM. HC Wainwright increased their price objective on Axsome Therapeutics from $180.00 to $185.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Morgan Stanley increased their price target on Axsome Therapeutics from $194.00 to $196.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Bank of America lifted their price objective on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Royal Bank Of Canada increased their target price on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the company an “outperform” rating in a research report on Tuesday, November 4th. Finally, Mizuho raised their target price on shares of Axsome Therapeutics from $200.00 to $202.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $179.88.

Get Our Latest Analysis on Axsome Therapeutics

Axsome Therapeutics Trading Down 0.6%

Shares of AXSM stock opened at $150.36 on Wednesday. The stock has a 50-day simple moving average of $129.95 and a 200 day simple moving average of $116.62. The stock has a market capitalization of $7.58 billion, a P/E ratio of -29.66 and a beta of 0.50. Axsome Therapeutics, Inc. has a fifty-two week low of $75.56 and a fifty-two week high of $152.94. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The business had revenue of $170.99 million during the quarter, compared to analyst estimates of $162.96 million. Axsome Therapeutics’s revenue for the quarter was up 63.2% on a year-over-year basis. On average, sell-side analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

About Axsome Therapeutics

(Free Report)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

Further Reading

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).